Premium
SARS‐CoV‐2 infection among patients with haematological disorders: Severity and one‐month outcome in 66 Danish patients in a nationwide cohort study
Author(s) -
Glenthøj Andreas,
Jakobsen Lasse H.,
Sengeløv Henrik,
Ahmad Syed A.,
Qvist Kristian,
Rewes Annika,
Poulsen Christian B.,
Overgaard Ulrik M.,
Mølle Ingolf,
Severinsen Marianne T.,
Strandholdt Casper N.,
Maibom Jack,
Kodahl Annette R.,
Ryg Jesper,
Ravn Pernille,
Johansen Isik S.,
Helsø Søren N.,
JensenFangel Søren,
Kisielewicz Jacek,
Wiese Lothar,
Helleberg Marie,
Kirk Ole,
Clausen Michael R.,
Frederiksen Henrik
Publication year - 2021
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13519
Subject(s) - medicine , comorbidity , neutropenia , hematology , intensive care unit , multiple myeloma , prospective cohort study , pediatrics , chemotherapy
Objectives Patients with haematological disorders may be particularly vulnerable to respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection; however, this is unknown. Methods We conducted a prospective, nationwide study including 66 patients in follow‐up at Danish haematology departments with a malignant or non‐malignant haematological disorder and with verified SARS‐CoV‐2 infection. Outcomes were intensive care unit (ICU) admission and one‐month survival rate. Results Mean age was 66.7 years, 60.6% were males, 90.9% had comorbidity, and 13.6% had a BMI ≥ 30. The most frequent diagnoses were chronic lymphocytic leukaemia/lymphoma (47.0%), multiple myeloma (16.7%) and acute leukaemia/myelodysplastic syndrome (AL/MDS) (12.1%). Treatment for the haematological disease was ongoing in 59.1% of cases. Neutropenia was present in 6.5%, lymphopenia in 46.6% and hypogammaglobulinaemia in 26.3%. The SARS‐CoV‐2 infection was mild in 50.0%, severe in 36.4% and critical in 13.6%. After one month, 21.2% had been admitted to ICU, and 24.2% died. Mortality was highest in older patients, patients with severe/critical SARS‐CoV‐2 infection, high comorbidity score or high performance status score, purine analogue treatment and with AL/MDS. Although older patients and patients with comorbidities had the highest mortality rates, mortality was considerable among all haematological patients. Conclusion Haematological patients with SARS‐CoV‐2 infection has a severe clinical course.